Publications by authors named "Hendrati Pirc-Danoewinata"
Article Synopsis
- Recent findings indicate that Imatinib (STI571) can lead to complete cytogenetic responses in patients with chronic myeloid leukemia (CML) who relapse after receiving stem cell transplants.
- A case study of a 43-year-old woman shows significant improvements after starting Imatinib, including a decrease in BCR/ABL transcripts and no detection of Ph+ cells after six months of treatment.
- The patient has maintained complete remission for 36 months, highlighting the potential of Imatinib for long-term management of relapsed CML after allogeneic stem cell transplantation.
The t(12;14)(q23;q32) breakpoints in a case of B-cell chronic lymphocytic leukemia (B-CLL) were mapped by fluorescence in situ hybridization (FISH) and Southern blot analysis and cloned using an IGH switch-gamma probe. The translocation affected a productively rearranged IGH allele and the carbohydrate (chondroitin 4) sulfotransferase 11 (CHST11) locus at 12q23, with a reciprocal break in intron 2 of the CHST11 gene. CHST11 belongs to the HNK1 family of Golgi-associated sulfotransferases, a group of glycosaminoglycan-modifying enzymes, and is expressed mainly in the hematopoietic lineage.
View Article and Find Full Text PDFBackground And Objectives: Rearrangements of the EVI-1 locus in chromosome band 3q26 are associated with a poor prognosis in myeloid malignancies. To aid the diagnosis of such aberrations, and possibly disease monitoring, we established an interphase fluorescence in situ hybridization (FISH) assay for the affected breakpoint region.
Design And Methods: Several overlapping PAC (P1-derived artificial chromosome) clones centromeric to the EVI-1 gene were labeled with a red fluorescent dye, and PAC clones telomeric to EVI-1 with a green fluorochrome.